Skip to main content
padlock icon - secure page this page is secure

An Open-Label Study of Risperidone in the Improvement of Quality of Life and Treatment of Symptoms of Violent and Self-Injurious Behaviour in Adults with Intellectual Disability

Buy Article:

$59.00 + tax (Refund Policy)


We examined the benefits of risperidone, including quality of life (QoL), in the treatment of violent and self-injurious behaviour in adults with moderate, severe or profound intellectual disability. Methods 

Twenty-four participants received open-label, oral, flexible-dose risperidone of 0.5–6 mg/day for 12 weeks. Efficacy was measured primarily using the Aberrant Behaviour Checklist (ABC) and secondarily using validated measures of depression, autism, QoL and global condition. Safety and tolerability were also assessed. Results 

Total ABC significantly improved from baseline by week 1. This improvement was maintained throughout the study (final visit, P < 0.001). Secondary efficacy measures were also improved with risperidone, including QoL measures (final visit: home life, P < 0.001; activity, P = 0.002; skills, P = 0.014). Risperidone was generally well tolerated, with no unexpected adverse events. Conclusions 

In this open-label trial, risperidone was efficacious and well tolerated for managing violent and self-injurious behaviour and improving QoL in adults with moderate, severe or profound intellectual disability.
No References
No Citations
No Supplementary Data
No Article Media
No Metrics

Keywords: disruptive behaviour disorders; intellectual disability; quality of life; risperidone

Document Type: Research Article

Affiliations: 1: School of Human and Health Sciences, University of Huddersfield, Huddersfield 2: Janssen-Cilag Ltd, Buckinghamshire, UK

Publication date: May 1, 2007

  • Access Key
  • Free content
  • Partial Free content
  • New content
  • Open access content
  • Partial Open access content
  • Subscribed content
  • Partial Subscribed content
  • Free trial content
Cookie Policy
Cookie Policy
Ingenta Connect website makes use of cookies so as to keep track of data that you have filled in. I am Happy with this Find out more